InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

Current share price for RAD : $0.009 0.001 (10%)+

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 FDA green light for diagnostic Phase 1 pancreatic trial 17 Oct 2023 10:10AM $0.135 $0.009 fallen by 93.33%
$39 RAD receives approval for Phase 1 therapeutic study of NSCLC 9 Oct 2023 9:35AM $0.130 $0.009 fallen by 93.08%
$39 ESG Report 28 Sep 2023 5:04PM $0.120 $0.009 fallen by 92.50%
$39 Appendix 4G 28 Sep 2023 5:01PM $0.120 $0.009 fallen by 92.50%
$39 Corporate Governance Statement 28 Sep 2023 4:59PM $0.120 $0.009 fallen by 92.50%
$39 Annual Report to shareholders 28 Sep 2023 4:55PM $0.120 $0.009 fallen by 92.50%
$39 Appendix 4E and FY23 Financial Report 31 Aug 2023 11:38AM $0.092 $0.009 fallen by 90.22%
$39 TerThera Terbium-161 isotope supply agreement expanded 24 Aug 2023 9:53AM $0.088 $0.009 fallen by 89.77%
$39 Results of Meeting 18 Aug 2023 10:40AM $0.087 $0.009 fallen by 89.66%
$39 EGM Presentation 18 Aug 2023 8:40AM $0.087 $0.009 fallen by 89.66%
$39 Change of Director's Interest Notice IT 8 Aug 2023 9:36AM $0.093 $0.009 fallen by 90.32%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 9:40AM $0.099 $0.009 fallen by 90.91%
$39 Dr Sherin Al-Safadi appointed VP Medical & Corporate Affairs 24 Jul 2023 9:19AM $0.110 $0.009 fallen by 91.82%
$39 Notice of Extraordinary General Meeting/Proxy Form 20 Jul 2023 9:24AM $0.110 $0.009 fallen by 91.82%
$39 Notification of cessation of securities - RAD 30 Jun 2023 2:57PM $0.110 $0.009 fallen by 91.82%
$39 Notification regarding unquoted securities - RAD 30 Jun 2023 2:53PM $0.110 $0.009 fallen by 91.82%
$39 Pivalate educational webinar 14 June 2023 13 Jun 2023 8:39AM $0.125 $0.009 fallen by 92.80%
$39 FDA Pre-IND meeting supports an IND application for RAD 101 29 May 2023 11:25AM $0.140 $0.009 fallen by 93.57%
$39 RAD 301 receives FDA Orphan Drug Designation 9 May 2023 9:54AM $0.170 $0.009 fallen by 94.71%
$39 Application for quotation of securities - RAD 28 Apr 2023 12:07PM $0.200 $0.009 fallen by 95.50%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2023 3:05PM $0.210 $0.009 fallen by 95.71%
$39 Agreement with TerThera to supply Terbium-161 isotope 17 Apr 2023 9:43AM $0.175 $0.009 fallen by 94.86%
$39 Radiopharm Receives $1.56M R&D Tax Incentive 28 Mar 2023 9:23AM $0.175 $0.009 fallen by 94.86%
$39 Radiopharm to participate in Jefferies Radiopharma Summit 28 Mar 2023 8:36AM $0.175 $0.009 fallen by 94.86%
$39 RAD and GenesisCare to Develop Novel Radiopharmaceuticals 27 Mar 2023 9:21AM $0.155 $0.009 fallen by 94.19%

301 - 325 of 617 results

Page 13 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.